Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 12
2021 9
2022 8
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
"Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.".
Pala L, Sala I, Pagan E, De Pas T, Zattarin E, Catania C, Cocorocchio E, Rossi G, Laszlo D, Ceresoli G, Canzian J, Valenzi E, Bagnardi V, Conforti F. Pala L, et al. Among authors: zattarin e. Breast. 2024 Feb;73:103672. doi: 10.1016/j.breast.2024.103672. Epub 2024 Jan 19. Breast. 2024. PMID: 38244459 Free PMC article.
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi CA, Guarneri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. Ther Adv Med Oncol. 2023 Dec 20;15:17588359231204857. doi: 10.1177/17588359231204857. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38130467 Free PMC article.
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Conforti F, Pala L, De Pas T, Zattarin E, Catania C, Cocorocchio E, Rossi G, Laszlo D, Colleoni M, Zambelli A, Hortobagyi GN, Cortes J, Piccart MJ, Dowsett M, Gelber RD, Viale G. Conforti F, et al. Among authors: zattarin e. Clin Cancer Res. 2024 Mar 15;30(6):1093-1103. doi: 10.1158/1078-0432.CCR-23-1836. Clin Cancer Res. 2024. PMID: 37906083
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.
Zattarin E, Taglialatela I, Lobefaro R, Leporati R, Fucà G, Ligorio F, Sposetti C, Provenzano L, Azzollini J, Vingiani A, Ferraris C, Martelli G, Manoukian S, Pruneri G, de Braud F, Vernieri C. Zattarin E, et al. Crit Rev Oncol Hematol. 2023 Oct;190:104109. doi: 10.1016/j.critrevonc.2023.104109. Epub 2023 Aug 27. Crit Rev Oncol Hematol. 2023. PMID: 37643668 Review.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. NPJ Breast Cancer. 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1. NPJ Breast Cancer. 2023. PMID: 37069173 Free PMC article.
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Provenzano L, Lobefaro R, Ligorio F, Zattarin E, Zambelli L, Sposetti C, Presti D, Montelatici G, Ficchì A, Martinetti A, Arata A, Del Vecchio M, Lauria Pantano C, Formisano B, Bianchi GV, Capri G, de Braud F, Vernieri C, Fucà G. Provenzano L, et al. Among authors: zattarin e. Ther Adv Med Oncol. 2023 Apr 13;15:17588359231165978. doi: 10.1177/17588359231165978. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37063779 Free PMC article.
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials.
Pala L, De Pas T, Pagan E, Sala I, Catania C, Zattarin E, Arnone P, Grassi MM, Colleoni M, Wolff AC, Cortes J, Piccart M, Gelber RD, Viale G, Bagnardi V, Conforti F. Pala L, et al. Among authors: zattarin e. Breast. 2023 Jun;69:258-264. doi: 10.1016/j.breast.2023.02.012. Epub 2023 Mar 2. Breast. 2023. PMID: 36898259 Free PMC article.
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Lobefaro R, et al. Among authors: zattarin e. Clin Breast Cancer. 2023 Apr;23(3):e151-e162. doi: 10.1016/j.clbc.2022.12.008. Epub 2022 Dec 17. Clin Breast Cancer. 2023. PMID: 36599769 Free article.
37 results